NCT00106613View on ClinicalTrials.gov

A Research Study for Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2003

Primary Completion Date

August 1, 2004

Study Completion Date

August 1, 2004

Conditions
Carcinoma, Renal CellNeoplasm Metastasis
Interventions
DRUG

FK228 (romidepsin)

Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.

Trial Locations (3)

60637

University of Chicago, Chicago

91010

City of Hope National Medical Center, Duarte

98109-1023

Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY